Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients

This study has been completed.
Sponsor:
Collaborators:
National Medical University, Ukraine
Immunitor USA Inc.
Information provided by (Responsible Party):
Lisichansk Regional Tuberculosis Dispensary
ClinicalTrials.gov Identifier:
NCT01222338
First received: June 30, 2010
Last updated: August 2, 2012
Last verified: August 2012

June 30, 2010
August 2, 2012
January 2010
December 2010   (final data collection date for primary outcome measure)
primary endpoint: sputum smear conversion [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Sputum smear conversion at monthly intervals timepoint Rates of pulmonary healing by chest X-ray at the end of study
Same as current
Complete list of historical versions of study NCT01222338 on ClinicalTrials.gov Archive Site
  • liver function [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    To determine the safety of V5+ATT versus ATT+placebo in TB-infected subjects, Standard parameters, e.g., ALT and bilirubin, liver size will be measured.
  • quality of life [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Measure changes in quality of life by TB score questionnaire
  • hematology parameters [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Measure CBC by standard routine methods
  • weight gain [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Measure changes in body weight
Same as current
Not Provided
Not Provided
 
Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients
Phase 2 Placebo-controlled, Randomized Study of Oral Immunomodulator in TB and TB/HIV Patients

Treatment of multidrug-resistant TB (MDR-TB) is 100 times more expensive than treatment of drug-susceptible TB, requiring intensive clinical management for prolonged time (18-24 months) and more toxic treatment course. In prior open label study the investigators have shown that adding V-5 Immunitor (V5), can reduce treatment duration to one month and enhance by 4-5 fold the efficacy of TB drugs. Furthermore, V5 has been shown to reverse or reduce liver damage caused by chemotherapy. The cost of V5 will be very modest. The investigators propose to conduct placebo-controlled clinical trial in patients with treatment refractory TB so that the clinical benefit of V5 is confirmed.

The first-diagnosed Mycobacterium tuberculosis infection (TB) is curable with the first line of anti-tuberculosis drugs (ATT) in over 90% of cases within 6 months. The treatment of TB, refractory to conventional ATT, requires the deployment of second line TB drugs. This represents a significant challenge, particularly in resource-poor countries.

The incidence of TB in Ukraine prior to 1992 was about 40 cases per 100,000 people. Ten years later, TB cases increased to over 80/100,000, with mortality doubled from 10.2/100,000 to 21.6/100,000. Drug-resistant TB is now common in Ukraine. Isoniazid and rifampicin resistance, which defines the MDR-TB, has been found in 44% and 32.9% of TB isolates. The first Ukrainian case of HIV was reported in 1987. Today, Ukraine has the highest HIV rate in the Eastern Europe, with increasing proportion of dual infection. For example, in 2002 the prevalence of TB and HIV co-infection was 6.3%, but in 2006 at least 15.5 % of TB patients had HIV co-infection.

It is clear that alternative and improved treatment options are needed. If such an intervention is found, the impact on the healthcare and clinical management of treatment-refractory TB and TB-HIV patients will be tremendous. The significant efforts are directed at finding new drugs and vaccines against TB. Immune-based interventions are actively sought as an adjunct therapy to conventional ATT. In earlier study the investigators have accidentally observed that when patients with chronic hepatitis C and HIV-TB were given V5 together with TB drugs it resulted in negative sputum conversion in 95% of patients within one month. This startling finding had prompted this study. The aim of the present study is to compare the clinical benefit of TB therapy in combination with V5 versus combination of placebo with ATT in a representative population of patients who are poorly manageable due to relapsing TB, MDR-TB, or TB-HIV co-infection.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Tuberculosis
Biological: V-5 immunitor
once per day dosing for 2 months
Other Name: V5, V-5 immunitor
  • Active Comparator: Immunomodulator intervention
    Two cohorts or arms of at least 60 subjects each (total 120) with pulmonary TB positive for sputum AFB smear will be randomized in a 1:1 ratio to receive once-daily, tablet of V-5 immunitor in combination with standard ATT for 2 months followed by ATT outside of trial for next 4 months or however long it needs to be.
    Intervention: Biological: V-5 immunitor
  • Placebo Comparator: placebo
    Control Cohort 1 (60 subjects) will receive standard first-line ATT regimen: (daily Isoniazide (H) 150mg, Rifampicin (R) 300mg, Ethambutol (E) 400mg, and Pyrazinamide (Z) 400mg during first 2 months, followed by H/R three times per week for the next 4 months. Patients also will receive placebo preparation, appearing identical to V-5 immunitor, taken once daily 30 minutes prior or after meal for 2 months
    Intervention: Biological: V-5 immunitor
Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Frolov VM, Tarakanovskaya MG, Batdelger D, Jirathitikal V, Bourinbaiar AS. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Immunotherapy. 2011 Feb;3(2):181-91. doi: 10.2217/imt.10.96. Epub 2010 Dec 24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
123
January 2011
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who are at least 18 years old and are willing and capable of providing written-informed consent.
  • Both men and non-pregnant women will be included.
  • One group of 30 patients will have HIV.
  • Another group of 30 patients will have drug-resistant TB (MDR or XDR).
  • Remaining 60 patients will have drug-sensitive TB of which 30 will be assigned to placebo.
  • TB infection documented prior to Study Entry by either the presence of TB rapid test or sputum smear positive for acid-fast bacilli (AFB).
  • At least two independent tests are sought to confirm TB diagnosis.
  • Agreement to participate in the study and to give a sample of blood for HIV testing.

Exclusion Criteria:

  • Subjects who have already taken V5 in prior trial and those without baseline data.
  • Those who met inclusion criteria can be retrospectively enrolled.
  • Those who are re-treated and relapsed will be eligible as long as they are on the same drug regimen as the rest of patients.
  • Pregnant or breast-feeding women are excluded.
  • Subjects who have taken anti-retroviral drugs or immunomodulatory therapies within 2 months prior to Entry:

    • systemic corticosteroids
    • immune globulin (IV gamma globulin, IVIG)
    • interferons,
    • interleukins
    • pentoxifylline (Trental)
    • thalidomide
    • filgrastim (G-CSF)
    • sargramostim (GM-CSF)
    • dinitrochlorobenzene (DNCB)
    • thymosin alpha 1 (thymosin alpha)
    • thymopentin
    • inosiplex (Isoprinosine)
    • polyribonucleoside (Ampligen)
    • ditiocarb sodium (Imuthiol)
    • any locally available immune modulators
    • and any other therapeutic or preventive vaccine.
  • Subjects requiring concurrent participation in another experimental research treatment study, or who received an experimental agent within four weeks prior to Study Entry.
  • Medical conditions that in the opinion of the local investigator, may obscure the proper observation of the safety or activity of the study treatment; including any acute medical condition of unknown etiology or recent surgery prior to Entry.
  • Medical conditions such as active alcohol or substance abuse, or psychological issues that in the opinion of the local investigator, would interfere with adherence to the requirements of this study.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Ukraine
 
NCT01222338
imm01
Yes
Lisichansk Regional Tuberculosis Dispensary
Lisichansk Regional Tuberculosis Dispensary
  • National Medical University, Ukraine
  • Immunitor USA Inc.
Principal Investigator: Dmytro Butov, MD Kharkiv National Medical University
Lisichansk Regional Tuberculosis Dispensary
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP